drugset
drugset / Trial / NCT06435039

A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers

NCT06435039 ↗

Phase 1 Terminated 12 enrolled Syneos Health Asieris Pharmaceuticals (AUS) Pty Ltd. · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of the study is to assess safety and tolerability following administration of single doses of APL-1202 (immediate release) IR tablets and APL-1501 extended release (ER) capsules in healthy participants.

Timeline

Start
2024-06-21
Primary completion
2024-07-16
Completion
2024-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject APL-1202 Unknown 375 mg Oral
Subject APL-1501 Unknown 764 mg Oral
Subject APL-1501 Unknown 1146 mg Oral
Subject APL-1501 Unknown 1528 mg Oral

Indications

No indication recorded.